Immunohistochemical expression of mismatch repair proteins, P53, and estrogen receptors in endometrial cancer: a retrospective study
Egyptian Journal of Pathology · 2026-01 · 46 (1) · 53-62
DOI: 10.4103/egjp.egjp_28_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Egyptian Journal of Pathology, online erschienen am 21.07.2026. Verfasst von Somia A.M. Soliman und 2 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy. It has complex molecular pathways, many of which affect its prognosis, such as mismatch repair (MMR), P53, and estrogen receptor (ER) status.
Objectives
The aim was to evaluate the immunohistochemical expression of MMR, P53, and ER in EC and correlate it with relevant clinicopathological features and the outcome of the disease. Materials and methods Fifty archived paraffin blocks of invasive EC cases that were diagnosed between January 2019 and December 2021. Samples were studied for immunohistochemical expression of MMR proteins; MLH1, MSH2, MSH6, and PMS2 (proficient vs. deficient), P53 (wild vs. mutant), and ER expression.
Results
Around 76% of the cases were of the endometrioid type. The age of the patients ranged between 35 and 89. Most of the cases (60%) were FIGO grade II. For MMR protein immunostaining, 70% of the cases were MMR proficient. There is no statistically significant difference between MMRd or MMRp cases as regards tumor grade, T stage, nodal status, depth of myometrial invasion, LVI, rate of recurrence, or disease-related mortality. P53 mutation was observed in 50% of cases. P53 mutation was associated with poor prognostic factors, including grade III, serous type carcinoma, deep myometrial invasion, and ER-negative immunostaining. Five out of the seven cases who died in our cohort were P53 mutated; however, there was no statistically significant correlation between P53 status and survival outcome. The only case that showed disease recurrence in our cases was P53 mutated.
Conclusion
P53 mutation is an indicator of poor prognosis, while positive ER staining is associated with good prognostic factors.
Zitieren
APA
Soliman, S. A., Mohamed, M. E., & El-kherbetawy, M. (2026). Immunohistochemical expression of mismatch repair proteins, P53, and estrogen receptors in endometrial cancer: a retrospective study. Egyptian Journal of Pathology, 46(1), 53-62. https://doi.org/10.4103/egjp.egjp_28_25
Vancouver
Soliman SA, Mohamed ME, El-kherbetawy M. Immunohistochemical expression of mismatch repair proteins, P53, and estrogen receptors in endometrial cancer: a retrospective study. Egyptian Journal of Pathology. 2026;46(1):53-62. doi:10.4103/egjp.egjp_28_25
BibTeX
@article{Soliman2026,
author = {Soliman, Somia A.M. and Mohamed, Mohamed E. and El-kherbetawy, Mohamed},
title = {Immunohistochemical expression of mismatch repair proteins, P53, and estrogen receptors in endometrial cancer: a retrospective study},
journal = {Egyptian Journal of Pathology},
year = {2026},
volume = {46},
number = {1},
pages = {53--62},
doi = {10.4103/egjp.egjp_28_25}
}
EUVIMED